skip to Main Content

IBT Receives Phase I SBIR grant from NIAID for development of Novel ISTAb therapeutics for Staph aureus

March 1, 2019

IBT in collaboration with Dr. Jean Lee lab at Brigham and Women Hospital, Harvard University, received a collaborative SBIR grant from NIH, entitled ISTAb: A novel therapy to target staphylococcal toxins at the site of infection.

Staphylococcus aureus (SA) is a Gram-positive human pathogen that causes a wide range of diseases from skin and soft tissue infections (SSTI) to life threatening sepsis and pneumonia. Numerous virulence factors, including cell surface proteins and polysaccharides, as well as secreted toxins are involved in SA pathogenesis. The cytolytic toxins kill key immune cells, allowing the pathogen to evade the immune response, induce tissue damage, and promote bacterial dissemination and metastatic growth in distant organs. There are currently no vaccine or immunotherapeutics against S. aureus.

In this Phase I SBIR, led by Dr. Rajan P. Adhikari, we will target neutralizing anti-toxin antibodies to the site of SA infection by taking advantage of the cell wall targeting (CWT) domain of lysostaphin (lyso) that specifically binds to the SA cell wall. The isolated CWT domain will be fused to specific anti-toxin monoclonal antibodies (mAbs) to generate Infection Site Targeted anti-toxin Antibodies (ISTAbs). A number of engineered candidates will be produced and tested in animal models of S. aureus invasive disease to select a preclinical candidate therapeutic.

IBT Receives Phase I/II Fast Track SBIR grant from NIAID for development of broadly protective monoclonal antibodies against Influenza Virus

March 1, 2019

IBT in collaboration with Abviro, LLC (Bethesda, MD) received a collaborative SBIR grant from NIH, entitled Development of a Universal Immunotherapeutic for Influenza Viruses.

Influenza virus (INFV) results in global seasonal and pandemic outbreaks estimated to cause severe illness in 3 to 5 million people annually causing significant morbidity and economic impact. Vaccination is currently the most effective disease control intervention, but constant annual surveillance of circulating viruses is necessary to predict effective vaccine composition. Currently available influenza drugs only result in modest clinical efficacy with limited effectiveness due to viral resistance.

In this fast track SBIR IBT and Abviro will perform advanced development activity for the lead product 3I14 as broad-spectrum antibody therapeutic against multiple influenza A strains.  In phase I, we will establish a highly productive stable CHO Research Cell Bank and generate a characterized stable lot of 3I14 to support phase II objectives. Phase II will characterize the 3I14 dose response in INFV A mouse models and therapeutic window, establish the pharmacokinetics and tolerability of 3I14 in mice, and confirm 3I14 does not lose potency as a result of viral resistance. Completion of these studies will position the product for IND-enabling manufacturing, efficacy and toxicology studies necessary to advance 3I14 to clinical studies.


IBT Receives Phase I SBIR grant from NIAID for development of monoclonal antibodies against Marburg Virus using a novel discovery platform

March 1, 2019


IBT in collaboration with the laboratory of Dr. Brandon Dekosky, at the University of Kansas, and Dr. Tom Geisbert laboratory and University of Texas Medical Branch (UTMB) receive a collaborative SBIR grant from NIH, entitled Mining natively paired macaque antibodies for Marburg virus protective antibodies.

Marburg virus has caused highly lethal outbreaks in the last few decades.  Currently there is a paucity of immunotherapeutic options in the pipeline for treatment of this deadly diseases.  Under this grant IBT investigator Dr. Shweta Kailasan with work with Dr. Dekosky’s team to develop novel monoclonal antibodies using a new method for identification of natively paired heavy and light chains from B cells of macaques immunized with IBT’s proprietary vaccine candidates. These antibodies will be tested in rodents at UTMB to select lead therapeutic candidates.


IBT Receives Phase I SBIR grant from NIAID for development of rationally designed vaccines against multiple Ebolaviruses

January 1, 2018


IBT in collaboration with Integral Molecular (Philadelphia, PA) and US Army Medical Research Institute of Infectious diseases (USAMRIID) receive a collaborative SBIR grant from NIH, entitled Remodeled glycoprotein for broad protection against ebolaviruses.

Beside the Zaire strain of Ebolavirus other ebolaviruses such as Sudan virus, Bundibugyo virus as well as the more distant relative Marburg virus have caused highly lethal outbreaks.  As the nature of future ebolavirus disease outbreaks cannot be predicted, development of broadly protective vaccines for ebolaviruses is urgently needed.

Under the phase I of this SBIR, IBT and collaborators with generate a series of novel vaccine candidates based on engineering of ebolavirus glycoprotein. The vaccine candidates will be evaluated in rodents for their ability to protect against lethal challenge with various ebolaviruses.

IBT to expand development of its S. aureus vaccine, IBT-VO2

(BOSTON, MA) –– CARB-X, a global partnership led by Boston University, is awarding Integrated Biotherapeutics (IBT) of Rockville, Maryland, USA, $1.6 million to expand the development of its vaccine against Staphylococcus aureus,  including  Methicillin-resistant Staphylococcus aureus (MRSA) superbugs, so that…

Read More

ID Week

IDWeek 2019 Annual Conference October 2 - October 6 Attendees include Richard Alm, CARB-X Alliance Director. IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medical…

Read More
Back To Top
×Close search